TACI-Fc Fusion Proteins, Methods of Making and Uses Thereof
OwnerJianmin Fang, Zheng Liuinventors
Life of this patent
Estimating the term…
Abstract
The subject invention relates generally to novel biologically active TACI-Fc fusion proteins that bind to BLyS and/or APRIL and uses thereof. The invention also relates to methods for recombinant production of homogeneous TACI-Fc fusion proteins on a large scale.
Claims23
A TACI-Fc fusion protein that comprises a TACI polypeptide that consists of amino acids 13 to 119 of SEQ ID NO:1, or a fragment thereof that starts at any of amino acids 13 to 29 of SEQ ID NO:1, extends through, and terminates at, any of amino acids 105 to 119 of SEQ ID NO:1 and which binds to BLyS or APRIL or both, or a variant of said polypeptide or fragment thereof that has at least 75% sequence identity with said polypeptide or fragment and which binds to BLyS or APRIL or both;
- and wherein said fusion protein further comprises an Fc domain.
A method for recombinant production of homogeneous TACI-Fc fusion proteins, wherein said method comprises
- i) constructing a TACI DNA fragment that does not contain proprotein cleavage sites;
- ii) joining the TACI DNA fragment with a Fc DNA to obtain a TACI-Fc fusion DNA;
- iii) inserting the TACI-Fc fusion DNA into a plasmid;
- iv) transfecting host cells with the TACI-Fc fusion plasmid DNA,
- v) expressing the TACI-Fc fusion protein, and
- vi) recovering the TACI-Fc fusion protein.
A TACI-Fc fusion protein that comprises a TACI polypeptide consisting of SEQ ID NO:1 or a fragment thereof that binds to BlyS or APRIL or both, and which has had the PC cleavage sites at amino acids 12 and 120 removed.
Dependencies are inferred from the claim text.